Postpartum haemorrhage: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data  by Kerr, Robbie et al.
P
c
R
S
J
P
a
b
c
d
e
f
g
h
i
j
a
A
K
P
A
I
G
C
1
1
c
h
a
d
g
o
i
r
T
s
h
0
AVaccine  (2016)  
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
ostpartum  haemorrhage:  Case  deﬁnition  and  guidelines  for  data
ollection,  analysis,  and  presentation  of  immunization  safety  data
obbie  Kerra,  Linda  O.  Eckertb, Beverly  Winikoff c, Jill  Durocherc, Shireen  Mehera,
ue  Fawcusd,  Shuchita  Mundlee,  Ben  Molf, Sabaratnam  Arulkumarang, Khalid  Khanh,
ulius  Wandwabwai, Sonali  Kochhar j, Andrew  Weeksa,∗, The  Brighton  Collaboration
rimary  Postpartum  Haemorrhage  Working  Group1
University of Liverpool, UK
University of Washington, WA,  USA
Gynuity Health Projects, NY, USA
Mowbray Maternity Hospital, South Africa
Government Medical College and Hospital Nagpur, India
University of Adelaide, Australia
St George’s University of London, UK
Barts and The London School of Medicine and Dentistry, UK
Busitema University, Mbale Regional Referral Hospital, Uganda
Global Healthcare Consulting, India
 r  t  i  c  l  e  i  n  f  o
rticle history:
34 6102–6109
vailable online 16 July 2016eywords:
ostpartum haemorrhage
dverse event
mmunization
uidelines
ase deﬁnition
. Preamble
.1. Need for developing case deﬁnitions and guidelines for data
ollection, analysis, and presentation for primary postpartum
aemorrhage as an adverse event following immunizationPostpartum haemorrhage (PPH) describes excessive bleeding
fter delivery of a foetus. It is the leading cause of maternal death,
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ecretariat@brightoncollaboration.org (A. Weeks).
1 Brighton Collaboration homepage: http://www.brightoncollaboration.org.
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264-410X/© 2016 Published by Elsevier Ltd. This is an open access article under the CC Bresponsible for approximately 68,500 deaths a year, 99.7% occur-
ring in developing regions [1]. It occurs in approximately 6% of
deliveries when deﬁned as a blood loss equal to, or greater than
500 ml,  or 1–2% when a 1000 ml  is used [2]. It therefore represents a
signiﬁcant global health burden, disproportionately affecting those
in the world’s poorest countries.
There is increasing interest into a broader role for vaccination in
the prevention of neonatal and pregnancy-related infections. How-
ever, it is vital that all vaccines are monitored for their potential
adverse effects, including their effect on key obstetric complica-
tions, such as postpartum haemorrhage. There is a need therefore
for consensus on a unifying deﬁnition of postpartum haemorrhage
to be used in vaccine trials, epidemiological and safety studies. Our
case deﬁnition aims to standardize the deﬁnition for research and
adverse event reporting. The purpose of this deﬁnition is not to
establish new clinical indicators or thresholds for deciding when
to treat post partum haemorrhage.
Postpartum haemorrhage is the consequence of several dif-
ferent pathologies that can occur in isolation or combination:
uterine atony, genital tract trauma, retained placental tissue and
Y license (http://creativecommons.org/licenses/by/4.0/).
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additional help, then a low volume of blood loss should be used,
to facilitate early treatment of the cause. If used for clinical trials,
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oagulation dysfunction. In severe cases of postpartum haemorr-
age often pathologies co-exist, with intractable haemorrhage
ften leading to coagulopathy. Uterine atony is regarded as the
ost common cause of PPH. It occurs when inadequate myome-
rial tone results in unchecked blood ﬂow to the placental
ed.
An individual’s risk of excessive blood loss will be inﬂuenced
y numerous pre-existing, pregnancy-related and obstetric fac-
ors. Risk factors for PPH include: Asian ethnicity; obesity; previous
PH; multiple pregnancy; anaemia; large baby; placenta prae-
ia; age over 40 years; induction of labour; prolonged labour;
ntrapartum pyrexia; placental abruption; episiotomy; operative
aginal delivery; retained placenta; and delivery by caesarean sec-
ion [3]. Incidence and severity of PPH will therefore vary widely
epending on the population studied and the obstetric practice.
PH-related adverse clinical events will also vary depending on the
ndividual. For example the same blood loss could have no clinical
onsequence in a healthy woman, but be a life-threatening event
or in a woman with severe anaemia.
The accurate quantiﬁcation of blood loss can be challenging.
stimation of blood loss has been shown to be inaccurate, with
nderestimation worsening at larger volumes [4,5]. Photometric
ethods, where the haemoglobin content of all swabs, drapes and
ads at delivery is examined in laboratory, offer the greatest accu-
acy [6]. The cost and logistics of these methods however mean
hey are used only in niche research studies. Direct measurement
ith an under-buttock, calibrated drape correlates with lab-based
ethods; although its accuracy depends on timely placement to
ollect blood without amniotic ﬂuid or urine [7]. Unfortunately the
outine use of a calibrated drape is not associated with a decrease in
evere PPH, therefore their routine use is mainly limited to research
8].
A World Health Organization technical working group in 1989
ndorsed a deﬁnition of a blood loss of “500 ml  or more from the
enital tract after delivery of the baby” [9]. They accepted that
his was “an arbitrary ﬁgure” and “not always of great clinical
igniﬁcance;” however, they decided against a greater volume as
the measurement of collected blood frequently and signiﬁcantly
nderestimates the actual blood loss.”
The Royal College of Obstetricians and Gynaecologists (UK) also
ndorse a deﬁnition based on 500 ml  or more [3]. However, in the
bsence of shock, they recommend only “readiness for resuscita-
ion” at this blood loss. If “major PPH” occurs, deﬁned by a blood loss
000 ml  or greater, they recommend “a full protocol of measures
o achieve resuscitation and haemostasis.” Similarly, the American
ongress of Obstetricians and Gynaecologists endorses a deﬁni-
ion of 1000 ml  or more “or any loss with symptoms or signs of
ypovolemia” [10].
Randomized trials investigating PPH treatments have used a
ange of blood loss volumes in their inclusion criteria, to iden-
ify women that could beneﬁt from treatment: 500 ml  [11–14],
00 ml  [15,16], 800 ml  [17], 1000 ml  [18] and 1500 ml  [19]. Other
uthors have used a fall in haemoglobin or haematocrit as a def-
nition, to avoid the difﬁculties of measurement or estimation of
lood loss [20,21]. The Cochrane Collaboration used blood loss of
000 ml  or more and maternal mortality as their primary outcomes
n their reviews of PPH preventions [22,23]. Non-Cochrane reviews
nd randomized trials of PPH preventions have used treatment-
ased criteria, such as the requirement of transfusion or additional
terotonics [24].
There is hence no uniformly accepted deﬁnition of postpartum
aemorrhage to use in a vaccination trials and surveillance sys-
ems. This is a missed opportunity as a deﬁnition would enhance
ata comparability, facilitate data interpretation and promote the
cientiﬁc understanding of postpartum haemorrhage as an adverse
vent. 
1.2. Methods for the development of the case deﬁnition and
guidelines for data collection, analysis, and presentation for
postpartum haemorrhage as an adverse events following
immunization
Following the process described on the Brighton Collabora-
tion Website http://www.brightoncollaboration.org/internet/en/
index/process.html, the Brighton Collaboration Postpartum Hae-
morrhage Working Group was  formed in 2015 and included
members of clinical and academic, but also public health and
epidemiology background. The composition of the working and ref-
erence group as well as results of the web-based survey completed
by the reference group with subsequent discussions in the work-
ing group can be viewed at: http://www.brightoncollaboration.org/
internet/en/index/working groups.html.
To guide the decision-making for the case deﬁnition and guide-
lines, a literature search was performed using the Cochrane library,
Medline (via Ovid), the Web  of Knowledge and Scopus, including
the terms [postpartum haemorrhage OR postpartum haemorrhage]
AND deﬁni-. The search resulted in the identiﬁcation of 295 refer-
ences. A further 24 references were found by searching of reference
lists, by web-search and through recommendation by working
group members. All abstracts were screened for deﬁnitions for
postpartum haemorrhage where a reference or rationale was  given.
All abstracts were in English language. 47 articles with potentially
relevant material were reviewed in full, in order to identify studies
using case deﬁnitions. This review resulted in a detailed summary
of 42 articles, including information on the study design, the deﬁni-
tion put forth, the rationale or references given, and any alternative
deﬁnitions mentioned. In addition, a summary of primary out-
comes used in trials evaluating interventions to prevent PPH; and
a summary of diagnostic criteria used in PPH treatment trials, were
distributed to working group members.
An inventory comprising of 34 relevant deﬁnitions of postpar-
tum haemorrhage was made available to working group members.
1.3. Rationale for selected decisions about the case deﬁnition of
postpartum haemorrhage as an adverse event following
immunization
The term “postpartum haemorrhage”
Postpartum haemorrhage is deﬁned by ICD-10 as “haemorrhage
after delivery of a foetus or infant” (ICD-10). If some bleeding after
delivery is universally expected, the key question is when does
bleeding become a haemorrhage, and normality become disease?
“Postpartum haemorrhage” is a widely accepted term, despite
lack of consensus on its deﬁnition. Authors and professional soci-
eties often use adjunctive terms (e.g. severe, major, massive) to
denote increased severity, but the use of these terms can also
be inconsistent [3,25–29]. There appears to be almost universal
acceptance of the terms “early” or “primary” to describe post-
partum haemorrhage that occurs within 24 h of delivery, and
“secondary” to describe haemorrhage occurring thereafter up to 42
days post-delivery. For the purposes of monitoring adverse events
following vaccination, both primary and secondary postpartum
haemorrhages are of potential interest. The working group there-
fore decided on the case deﬁnition of “postpartum haemorrhage”
as a term in isolation.
It is entirely appropriate for postpartum haemorrhage to have
different deﬁnitions depending on the purpose for which it is to
be used. If used as a threshold for a birth attendant calling for
   (2016) 6102–6109 6103audit or research then deﬁnitions using higher volumes of blood
loss and markers of maternal morbidity are of greater interest. The
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ine 346eﬁnition in this document is for the latter purpose, and must not
e mistaken as a clinical guide for when to start treatment.
Postpartum blood loss only becomes of interest to the individual
hen it causes symptoms or some dysfunction in the new mother.
e therefore have interest if it causes symptoms or affects the func-
ion as a continuum from “normal” to “haemorrhage”. There is not
 natural threshold.
To the new mother, postpartum blood loss is only signiﬁcant if
t causes symptoms or an adverse clinical event. We  therefore have
ocused this case deﬁnition on genital tract bleeding that “leads to
n adverse clinical outcome.” In the deﬁnition presented below,
evel I, with the highest speciﬁcity also represents the highest
everity. Within the deﬁnition context, however, the three diagnos-
ic levels must not be simply misunderstood as reﬂecting different
rades of clinical severity. They instead reﬂect diagnostic certainty
see below). The availability of diagnostic tools or treatments will
ary depending on the site. This may  determine what level of diag-
ostic certainty can be reached, although all levels are considered
cceptable.
dverse clinical outcomes
In clinical practice it is not the precise volume of blood loss that
s of concern, but rather the clinical condition of the woman  and the
esponse of her blood loss to treatment. Postpartum bleeding may
esult in symptoms of hypovolemia or anaemia e.g. exertional dys-
noea, postural presyncope, tiredness or reduced consciousness. At
he furthest extreme uncorrected hypovolaemic shock can lead to
rgan-dysfunction and maternal death.
Fortunately, in most settings, the initiation of resuscitation and
aemostatic measures prevents PPH morbidity and mortality. Man-
gement is often given in steps, assessing response to less invasive,
ower risk treatments ﬁrst, before moving onto invasive surgical
nterventions. As a result, use of these latter interventions for post-
artum haemorrhage can be used as a highly speciﬁc criterion for
 case deﬁnition.
The Working Group decided that genital tract bleeding that
eads to a maternal death, or maternal near miss (as deﬁned by
HO  [30]) warrants Level I, the highest certainty for postpartum
aemorrhage.
lood loss volumes
The use of blood loss volume is the long-established method to
eﬁne PPH [3,9,10]. If the blood loss is known then a volume cut-off
an be used to deﬁne when a PPH has occurred. The challenge is in
etermining where that cut-off should lie.
The working group hypothesized that there could be a single
lood loss volume cut-off that represents the optimum sensitivity
nd speciﬁcity for an adverse clinical outcome in a given population
.g. blood transfusion for PPH. To our knowledge there have been no
ublished studies presenting this analysis, or describing the inci-
ence of adverse events at each volume of blood loss. However,
npublished data from a trial that routinely measured blood loss
t 33, 055 deliveries, revealed the six patients with serious adverse
vents (hysterectomy or death) all had blood losses greater than
000 ml  [16].
The reverse approach is to examine the “normal” blood loss in a
ow-risk population; and deﬁne PPH as an upper centile of this. This
equires deliveries without third-stage prophylaxis, as it is proven
o decrease mean blood loss but is not available in every setting. The
orking group was given access to unpublished data of measured
lood losses from 9348 low-risk vaginal deliveries with no prophy-
axis and no treatment until blood loss exceeded 700 ml  [15]. Blood
osses of at least 500 ml,  700 ml  and 1000 ml  represented the 84th,
R. Kerr et al. / Vacc1049th and 97th centiles respectively.
The working group agreed that it is fair to assume the like-
ihood of adverse clinical outcomes increases with higher blood
osses. As no studies have validated the use of a volume cut-offsand any choice of a centile is arbitrary, it was  agreed to endorse an
already established cut-off. This deﬁnition uses 1000 ml  or more.
It is speciﬁc as it is a relatively rare occurrence, and sensitive
as signiﬁcant adverse clinical outcomes are unlikely under this
level.
Blood loss measurement or estimation
In response to the well-known inaccuracies of estimation, this
deﬁnition gives a greater level of diagnostic certainty to measured
blood loss of 1000 ml  or more (level 2). Estimated blood loss of
1000 ml  or more is included at level 3, as there are many settings
where measurement is not possible.
The working group recommends direct measurement of blood
loss by using a calibrated plastic drape placed under the buttocks
immediately following delivery over other methods [31]. Gravi-
metric, or decanting a bed-pan into a measuring jug, may  also be
used if care is taken to collect all the blood without contamination.
Weighing must be undertaken immediately, or the delivery swabs
placed in a sealed container, to avoid evaporation.
Clinical signs – vital signs
There will be instances where blood loss is difﬁcult to assess,
not documented, or not known (e.g. with patient transferred from
the community to a facility). The working group agreed that
these cases should ﬁt into deﬁnition, especially when they expe-
rience adverse outcomes or their vital signs indicate hypovolemic
shock.
In postpartum haemorrhage there is limited evidence validating
vital sign cut-offs. A recent systematic review on the relationship
between blood loss and clinical signs was  unable to establish spe-
ciﬁc vital sign cut-offs for interventions in PPH [32]. Shock index
(heart rate divided by systolic blood pressure) has been shown to
be a better predictor of adverse outcome in postpartum haemorr-
hage, than other vital signs [33,34]; but few studies have validated
a cut-off to be used [27].
The working group acknowledged the promise of shock index,
although agreed the present evidence was  insufﬁcient for inclusion.
The deﬁnition uses hypotension with genital tract bleeding at Level
2, as this has high speciﬁcity, and is already endorsed by WHO  in
their deﬁnition of severe postpartum haemorrhage (WHO).
Inﬂuence of treatment on fulﬁlment of case deﬁnition
The case deﬁnition uses treatment at levels 1 and 2. Genital
bleeding that leads to a hysterectomy or transfusion of ≥5 units
of blood reaches level 1 of certainty in this deﬁnition [30]. These
life-saving interventions use signiﬁcant resources and are associ-
ated with their own  morbidity; therefore it can be assumed their
use represents a high speciﬁcity for postpartum haemorrhage.
The requirement of blood transfusion is a valuable proxy for clin-
ical concern, especially as its availability is limited in many settings.
Practitioners may  advise transfusion in response to clinical signs,
perceived volume or rate of blood loss, laboratory investigations,
or patient symptoms. The consensus was for any blood transfused
in response to genital bleeding to meet level two  certainty of the
case deﬁnition.
First-line interventions in postpartum haemorrhage, for exam-
ple uterotonic medications or intravenous ﬂuids, are not used in
this deﬁnition. These treatments may  be initiated in response to a
perceived abnormal fast rate of blood loss that arrests well before
the 1000 ml  threshold. The use and availability of these interven-
tions will vary greatly between different settings.
Laboratory examinations – haemoglobin and haematocrit
The working group decided that a fall in haemoglobin or haema-
   (2016) 6102–6109tocrit measured before and after delivery did not have a place
in this deﬁnition. Although it represents an objective alternative
to estimated blood loss, it will be altered by the patient’s ﬂuid
status at the time of testing. There exists no consensus for the
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cine 34iming of the postnatal blood test and the investigator will face
he logistical challenge of blood collection a ﬁxed number of
ours following delivery. In addition, this approach is not valid
hen patients require a blood transfusion acutely for postpartum
aemorrhage. Finally, laboratory testing is not available in many
ettings.
ormulating a case deﬁnition that reﬂects diagnostic certainty: weigh-
ng speciﬁcity versus sensitivity
The case deﬁnition has been formulated such that the Level
 deﬁnition is highly speciﬁc for the condition. As maximum
peciﬁcity normally implies a loss of sensitivity, two  additional
iagnostic levels have been included in the deﬁnition, offering a
tepwise increase of sensitivity from Level 1 down to Level 3, while
etaining an acceptable level of estimated speciﬁcity at all levels. In
his way it is hoped that all possible cases of postpartum haemorr-
age can be captured.
It needs to be re-emphasized that the grading of deﬁnition lev-
ls is entirely about diagnostic certainty, not clinical severity of an
vent. Thus, a clinically very severe event may  appropriately be
lassiﬁed as Level 2 or 3 rather than Level One. Information about
he severity of the event should additionally always be recorded,
s speciﬁed by the data collection guidelines.
iming post immunization
A speciﬁc time frame for postpartum haemorrhage following
mmunization is not included as the literature review revealed no
ase reports or studies where a relationship was suggested. We
ostulate that a deﬁnition designed to be a suitable tool for testing
ausal relationships requires ascertainment of the outcome (e.g.
ostpartum haemorrhage) independent from the exposure (e.g.
mmunizations). Therefore, to avoid selection bias, a restrictive
ime interval from immunization to onset of postpartum haemorr-
age should not be an integral part of such a deﬁnition. Instead,
here feasible, details of this interval should be assessed and
eported as described in the data collection guidelines.
Further, postpartum haemorrhage often occurs outside the con-
rolled setting of a clinical trial or hospital. In some settings it may
e impossible to obtain a clear timeline of the event, particularly in
ess developed or rural settings. In order to avoid selecting against
uch cases, the Brighton Collaboration case deﬁnition avoids set-
ing arbitrary time frames.
uidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case deﬁnition is
ccompanied by guidelines which are structured according to
he steps of conducting a clinical trial, i.e. data collection, anal-
sis and presentation. Neither case deﬁnition nor guidelines are
ntended to guide or establish criteria for management of ill
nfants, children, or adults. Both were developed to improve data
omparability.
.4. Periodic review
Similar to all Brighton Collaboration case deﬁnitions and guide-
ines, review of the deﬁnition with its guidelines is planned on
 regular basis (i.e. every three to ﬁve years) or more often if
eeded.
. Case deﬁnition of postpartum haemorrhage
Postpartum haemorrhage is a condition characterized by
Level 1 of diagnostic certainty
R. Kerr et al. / VacGenital bleeding after delivery leading to severe maternal out-
come (maternal death or maternal near miss) as deﬁned by WHO
[28]. 
Level 2 of diagnostic certainty
• Genital bleeding after delivery with at least one of the following:
measured abnormal bleeding (1000 ml  or more), or any bleeding
leading to hypotension or blood transfusion.
Level 3 of diagnostic certainty
• Genital bleeding after delivery estimated at 1000 ml  or more
Terminology
“Delivery” is the birth of an offspring, which breathes or
shows evidence of life, or is born without signs of life at an esti-
mated gestation of 24 weeks or more (as deﬁned by Preterm Birth
guidelines)(http://www.brightoncollaboration.org).
“Maternal death” is the death of a woman while pregnant or
within 42 days of termination of pregnancy, irrespective of the
duration and the site of the pregnancy (as deﬁned by Maternal Death
guidelines (http://www.brightoncollaboration.org)).
3. Guidelines for data collection, analysis and presentation
of postpartum haemorrhage
It was the consensus of the Brighton Collaboration Postpartum
Haemorrhage Working Group to recommend the following guide-
lines to enable meaningful and standardized collection, analysis,
and presentation of information about postpartum haemorrhage.
However, implementation of all guidelines might not be possible
in all settings. The availability of information may  vary depend-
ing upon resources, geographical region, and whether the source
of information is a prospective clinical trial, a post-marketing
surveillance or epidemiological study, or an individual report of
postpartum haemorrhage. Also, as explained in more detail in the
overview paper in this volume, these guidelines have been devel-
oped by this working group for guidance only, and are not to be
considered a mandatory requirement for data collection, analysis,
or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the col-
lection of data on availability following immunization to allow
for comparability of data, and are recommended as an addition
to data collected for the speciﬁc study question and setting. The
guidelines are not intended to guide the primary reporting of Post-
partum haemorrhage to a surveillance system or study monitor.
Investigators developing a data collection tool based on these data
collection guidelines also need to refer to the criteria in the case
deﬁnition, which are not repeated in these guidelines. The Brighton
Collaboration has developed guidelines for data collection https://
brightoncollaboration.org/public/resources/standards/guidelines.
html; and data collection forms https://brightoncollaboration.org/
public/resources/data-collection-forms.html.
Guidelines numbers below have been developed to address data
elements for the collection of adverse event information as speci-
ﬁed in general drug safety guidelines by the International Confer-
ence on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use [35], and the form for reporting
of drug adverse events by the Council for International Organi-
zations of Medical Sciences [36]. These data elements include an
   (2016) 6102–6109 6105identiﬁable reporter and patient, one or more prior immunizations,
and a detailed description of the adverse event, in this case, of
postpartum haemorrhage following immunization. The additional
guidelines have been developed as guidance for the collection of
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ﬁbrinogen; clotting factors; and invasive surgical intervention
(including manual removal of placenta).
22) Outcome8 at last observation.
3 The date and/or time of onset are deﬁned as the time post immunization, when
the  ﬁrst sign or symptom indicative for postpartum haemorrhage occurred. This
may  only be possible to determine in retrospect.
4 The date and/or time of ﬁrst observation of the ﬁrst sign or symptom indicative
for  postpartum haemorrhage can be used if date/time of onset is not known.
5 The date of diagnosis of an episode is the day post immunization when the event
cine 346dditional information to allow for a more comprehensive under-
tanding of postpartum haemorrhage following immunization.
.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
ollowing information should be recorded:
) Date of report.
) Name and contact information of person reporting2 and/or
diagnosing the postpartum haemorrhage as speciﬁed by
country-speciﬁc data protection law.
) Name and contact information of the investigator responsible
for the subject, as applicable.
) Relation to the patient (e.g., immunizer [clinician, nurse], family
member [indicate relationship], other).
.1.2. Vaccine/control
.1.2.1. Demographics. For all cases and/or all study participants,
s appropriate, the following information should be recorded:
) Case/study participant identiﬁers (e.g. ﬁrst name initial followed
by last name initial) or code (or in accordance with country-
speciﬁc data protection laws).
) Date of birth, age, sex, race and ethnicity.
) For infants: Gestational age and birth weight.
.1.2.2. Clinical and immunization history. For all cases and/or
ll study participants, as appropriate, the following information
hould be recorded:
8) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms e.g.
anaemia, ﬁbroids, previous surgery, known or suspected coag-
ulopathies including platelet disorders. Past obstetric history:
parity, previous modes of delivery, previous PPH, previous
retained placenta. Obstetric history: gestation; presence of
antepartum bleeding; if induced- gestation and methods used;
timing of membrane rupture- spontaneous or amniotomy;
duration of ﬁrst, second and third stages of labour; presence of
intrapartum pyrexia; time and place of delivery; staff present at
delivery; mode of delivery; use of episiotomy; if operative-staff
cadre performing; birth weight; live or stillbirth; use of PPH
prophylaxis; presence of retained tissue; staff present during
treatment.
9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization including
prescription and non-prescription medication as well as med-
ication or treatment with long half-life or long term effect.
(e.g. immunoglobulins, blood transfusion and immunosup-
pressants).
0) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)).
.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
ollowing information should be recorded:
R. Kerr et al. / Vac1061) Date and time of immunization(s).
2) Description of vaccine(s) (name of vaccine, diluent, manufac-
turer, lot number, dose (e.g. 0.25 mL,  0.5 mL, etc.) and number
2 If the reporting centre is different from the vaccinating centre, appropriate and
imely communication of the adverse event should occur.of dose if part of a series of immunizations against the same
disease).
13) The anatomical sites (including left or right side) of all immun-
izations (e.g. vaccine A in proximal left lateral thigh, vaccine B
in left deltoid).
14) Route and method of administration (e.g. intramuscular, intra-
dermal, subcutaneous, and needle-free (including type and
size), other injection devices).
15) Needle length and gauge.
3.1.4. The adverse event
16) For all cases at any level of diagnostic certainty and for reported
events with insufﬁcient evidence, the criteria fulﬁlled to meet
the case deﬁnition should be recorded.
Speciﬁcally document:
17) Clinical description of signs and symptoms of postpartum hae-
morrhage, and if there was  medical conﬁrmation of the event
(i.e. patient seen by physician).
18) Date/time of onset,3 ﬁrst observation4 and diagnosis,5 end of
episode6 and ﬁnal outcome.7
19) Concurrent signs, symptoms, and diseases.
20) Measurement/testing
• The primary assessment is of postnatal volume of blood loss.
We  would recommend the calibrated under-buttock drape e.g.
BRASSS-V for direct measurement of blood loss. In the absence
of this, blood can be measured using a “fracture” bed-pan and
measuring jug, or weighing of absorbent materials.
• Table 1 gives a list of optimal clinical, laboratory and man-
agement criteria to be assessed in order to diagnose a WHO
maternal near-miss.
• Values and units of routinely measured parameters (e.g. blood
pressure, heart rate, blood loss) – in particular those indicating
the severity of the event. Hypotension in Level 2 of our case def-
inition should be deﬁned as a systolic blood pressure of under
90 mmHg.
• Method of measurement (e.g. type of sphygmometer, timing
of measurement, patient position, for blood loss-calibrated
under-buttock drape, bed pan and jug or gravimetric etc.);
• Results of laboratory examinations (especially haemoglobin,
haematocrit, platelet count and coagulation screen), surgical
and/or pathological ﬁndings and diagnoses if present.
21) Treatment given for postpartum haemorrhage, especially
oxytocin; ergometrine; prostaglandins including misopros-
tol; bimanual compression; aortic compression; transfusion
with whole blood; red cell concentrate; fresh frozen plasma;
   (2016) 6102–6109met  the case deﬁnition at any level.
6 The end of an episode is deﬁned as the time the event no longer meets the case
deﬁnition at the lowest level of the deﬁnition.
7 E.g. recovery to pre-immunization health status, spontaneous resolution, ther-
apeutic intervention, persistence of the event, sequelae, death.
8 An AEFI is deﬁned as serious by international standards if it meets one or
more of the following criteria: (1) it results in death, (2) is life-threatening, (3) it
requires inpatient hospitalization or results in prolongation of existing hospitaliza-
tion, (4) results in persistent or signiﬁcant disability/incapacity, (5) is a congenital
anomaly/birth defect, (6) is a medically important event or reaction.
Table 1
The WHO  maternal near miss criteria [28].
Clinical criteria Acute cyanosis
Gaspinga
Respiratory rate >40 or <6 min−1
Shockb
Oliguria non responsive to ﬂuids or diureticsc
Clotting failured
Loss of consciousness lasting ≥12 he
Loss of consciousness AND absence of pulse/heart
beat
Strokef
Uncontrollable ﬁt/total paralysisg
Jaundice in the presence of pre-eclampsiah
Laboratory-based
criteria
Oxygen saturation <90% for ≥60 min  pH < 7.1
PaO2/FiO2 <200 mmHg  Lactate >5
Creatinine >300 mmol/l or >3.5 mg/dl
Acute thrombocytopenia (<50,000 platelets)
Bilirubin >100 mmol/l or >6.0 mg/dl
Loss of consciousness AND the presence of glucose
and ketoacids in urine
Management-based
criteria
Use of continuous vasoactive drugsi
Intubation and ventilation for ≥60 min  not related to
anaesthesia
Hysterectomy following infection or haemorrhage
Dialysis for acute renal failure
Transfusion of ≥5 units red cell transfusion
Cardio-pulmonary resuscitation (CPR)
A woman  presenting with any of the following life-threatening conditions and sur-
viving a complication that occurred during pregnancy, childbirth or within 42 days
of  termination of pregnancy should be considered as a maternal near miss case.
(Criterion most relevant to postpartum haemorrhage in bold).
a Gasping is a terminal respiratory pattern and the breath is convulsively and
audibly caught.
b Shock is a persistent severe hypotension, deﬁned as a systolic blood pressure
<90 mmHg for ≥60 min  with a pulse rate at least 120 despite aggressive ﬂuid replace-
ment (>2l).
c Oliguria is deﬁned as an urinary output <30 ml/h for 4 h or <400 ml/24 h.
d Clotting failure can be assessed by the bedside clotting test or absence of clotting
from the IV site after 7–10 min.
e Loss of consciousness is a profound alteration of mental state that involves com-
plete or near-complete lack of responsiveness to external stimuli. It is deﬁned as a
Coma Glasgow Scale <10 (moderate or severe coma).
f Stroke is a neurological deﬁcit of cerebrovascular cause that persists beyond
24  h or is interrupted by death within 24 h.
g Condition in which the brain is in a state of continuous seizure.
h Pre-eclampsia is deﬁned as the presence of hypertension associated with pro-
teinuria. Hypertension is deﬁned as a blood pressure of at least 140 mmHg (systolic)
or  at least 90 mmHg  (diastolic) on at least two occasions and at least 4–6 h apart after
the  20th week of gestation in women known to be normotensive beforehand. Pro-
teinuria is deﬁned as excretion of 300 mg  or more of protein every 24 h. If 24-h
urine samples are not available, proteinuria is deﬁned as a protein concentration of
300  mg/l or more (≥1+ on dipstick) in at least two random urine samples taken at
least  4–6 h apart.
i For instance, continuous use of any dose of dopamine, epinephrine or norepi-
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3) Objective clinical evidence supporting classiﬁcation of the
event as “serious” 9.
4) Exposures other than the immunization 24 h before and after
immunization (e.g. food, environmental) considered poten-
tially relevant to the reported event.
9 To determine the appropriate category, the user should ﬁrst establish, whether
 reported event meets the criteria for the lowest applicable level of diagnostic
ertainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of
he  deﬁnition is met, and there is evidence that the criteria of the next higher level
f  diagnostic certainty are met, the event should be classiﬁed in the next category.
his approach should be continued until the highest level of diagnostic certainty
or a given event could be determined. Major criteria can be used to satisfy the
equirement of minor criteria. If the lowest level of the case deﬁnition is not met, it
hould be ruled out that any of the higher levels of diagnostic certainty are met  and
he event should be classiﬁed in additional categories four or ﬁve. 
3.1.5. Miscellaneous/general
25) The duration of surveillance for postpartum haemorrhage
should be predeﬁned based on
26) Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
27) Biologic characteristics of the vaccine-targeted disease;
28) Biologic characteristics of postpartum haemorrhage including
patterns identiﬁed in previous trials (e.g. early-phase trials);
and
29) Biologic characteristics of the vaccine (e.g. nutrition, underly-
ing disease like immunodepressing illness).
30) The duration of follow-up reported during the surveillance
period should be predeﬁned likewise. It should aim to continue
to resolution of the event.
31) Methods of data collection should be consistent within and
between study groups, if applicable.
32) Follow-up of cases should attempt to verify and complete the
information collected as outlined in data collection guidelines
1–24.
33) Investigators of patients with postpartum haemorrhage should
provide guidance to reporters to optimize the quality and com-
pleteness of information provided.
34) Reports of postpartum haemorrhage should be collected
throughout the study period regardless of the time elapsed
between immunization and the adverse event. If this is not fea-
sible due to the study design, the study periods during which
safety data are being collected should be clearly deﬁned.
3.2. Data analysis
The following guidelines represent a desirable standard for anal-
ysis of data on postpartum haemorrhage to allow for comparability
of data, and are recommended as an addition to data analyzed for
the speciﬁc study question and setting.
31) Reported events should be classiﬁed in one of the following
ﬁve categories including the three levels of diagnostic cer-
tainty. Events that meet the case deﬁnition should be classiﬁed
according to the levels of diagnostic certainty as speciﬁed in
the case deﬁnition. Events that do not meet the case deﬁnition
should be classiﬁed in the additional categories for analysis.
Event classiﬁcation in 5 categories10
Event meets case deﬁnition
1) Level 1: Criteria as speciﬁed in the postpartum haemorrhage
case deﬁnition
2) Level 2: Criteria as speciﬁed in the postpartum haemorrhage
case deﬁnition
3) Level 3: Criteria as speciﬁed in the postpartum haemorrhage
case deﬁnition
Event does not meet case deﬁnition
Additional categories for analysis
  4 (2016) 6102–6109 61074) Reported postpartum haemorrhage (either related to blood loss
volume or use of therapy) with insufﬁcient evidence to meet the
case deﬁnition11
10 If the evidence available for an event is insufﬁcient because information is miss-
ing,  such an event should be categorized as “Reported postpartum haemorrhage
with insufﬁcient evidence to meet the case deﬁnition”.
11 An event does not meet the case deﬁnition if investigation reveals a negative
ﬁnding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classiﬁed as “Not a case of postpartum haemorrhage”.
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causes of maternal death: a WHO  systematic analysis. Lancet Global Health
2014;2:e323–33.
[2] Carroli G, Cuesta C, Abalos E, Gulmezoglu AM.  Epidemiology of postpar-
tum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol
2008;22:999–1012.
ine 346) Not a case of postpartum haemorrhage
2) The interval between immunization and reported postpartum
haemorrhage could be deﬁned as the date/time of immuniza-
tion to the date/time of onset3 of the ﬁrst symptoms and/or
signs consistent with the deﬁnition. If few cases are reported,
the concrete time course could be analyzed for each; for a
large number of cases, data can be analyzed in the following
increments:
Subjects with PPH by Interval from immunization to PPH
nterval between immunization and PPH Number
–72  h after immunization
ore than 72 h to 7 days after immunization
ore than 7 days to 30 days after immunization
ore than 30 days after immunization (pregnant at time)
accination prior to pregnancy
otal
3) The duration of a possible postpartum haemorrhage could be
analyzed as the interval between the date/time of onset2 of the
ﬁrst symptoms and/or signs consistent with the deﬁnition and
the end of episode6 and/or ﬁnal outcome7. Whatever start and
ending are used, they should be used consistently within and
across study groups.
4) If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magni-
tude of the adverse experience could be used as the basis for
analysis. Analysis may  also include other characteristics like
qualitative patterns of criteria deﬁning the event.
5) The distribution of data (as numerator and denominator data)
could be analyzed in predeﬁned increments (e.g. measured
values, times), where applicable. Increments speciﬁed above
should be used. When only a small number of cases are pre-
sented, the respective values or time course can be presented
individually.
6) Data on postpartum haemorrhage obtained from subjects
receiving a vaccine should be compared with those obtained
from an appropriately selected and documented control
group(s) to assess background rates of hypersensitivity in non-
exposed populations, and should be analyzed by study arm and
dose where possible, e.g. in prospective clinical trials.
.3. Data presentation
These guidelines represent a desirable standard for the pre-
entation and publication of data on postpartum haemorrhage
ollowing immunization to allow for comparability of data, and
re recommended as an addition to data presented for the spe-
iﬁc study question and setting. Additionally, it is recommended to
efer to existing general guidelines for the presentation and pub-
ication of randomized controlled trials, systematic reviews, and
eta-analyses of observational studies in epidemiology (e.g. state-
ents of Consolidated Standards of Reporting Trials (CONSORT), of
mproving the quality of reports of meta-analyses of randomized
ontrolled trials (QUORUM), and of Meta-analysis Of Observational
tudies in Epidemiology (MOOSE), respectively) [37–39].
7) All reported events of postpartum haemorrhage should be pre-
sented according to the categories listed in guidelines.
8) Data on possible postpartum haemorrhage events should be
presented in accordance with data collection guidelines 1–24
and data analysis guidelines 31–36.
R. Kerr et al. / Vacc1089) Terms to describe postpartum haemorrhage such as “low-
grade”, “mild”, “moderate”, “high”, “severe” or “signiﬁcant” are
highly subjective, prone to wide interpretation, and should be
avoided, unless clearly deﬁned.40) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomi-
nator data are usually not readily available, attempts should be
made to identify approximate denominators. The source of the
denominator data should be reported and calculations of estimates
be described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
) The incidence of cases in the study population should be pre-
sented and clearly identiﬁed as such in the text.
) If the distribution of data is skewed, median and range are usually
the more appropriate statistical descriptors than a mean. How-
ever, the mean and standard deviation should also be provided.
) Any publication of data on postpartum haemorrhage should
include a detailed description of the methods used for data col-
lection and analysis as possible. It is essential to specify:
• The study design;
• The method, frequency and duration of monitoring for postpar-
tum haemorrhage
• The trial proﬁle, indicating participant ﬂow during a study includ-
ing drop-outs and withdrawals to indicate the size and nature of
the respective groups under investigation;
• The type of surveillance (e.g. passive or active surveillance);
• The characteristics of the surveillance system (e.g. population
served, mode of report solicitation);
• The search strategy in surveillance databases;
• Comparison group(s), if used for analysis;
• The instrument of data collection (e.g. standardized question-
naire, report form);
• Whether the day of immunization was considered “day one” or
“day zero” in the analysis;
• Whether the date of onset3 and/or the date of ﬁrst observation4
and/or the date of diagnosis5 was  used for analysis; and
• Use of this case deﬁnition for postpartum haemorrhage, in the
abstract or methods section of a publication.12
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